For any health or medical concerns, it is crucial to consult your primary care physician or a qualified healthcare professional.
In December 2024, the FDA approved Zepbound as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
The trial also showed improvements in the complications associated with obesity, including blood pressure, lipids, blood glucose, metabolic syndrome and quality of life
The injection can be given in the abdomen, thigh, or upper arm, and injection sites should be rotated to minimise injection-site reactions
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, Mcgowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF